Hospital
Parkview Hospital, INC.
Parkview Hospital, INC. was paid $93.04M by Medicaid between Jan 2018 and Dec 2024, across 276 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoPARKVIEW HOSPITAL, INC.
FORT WAYNE, IN 46845
FORT WAYNE, IN 46845
33aNPI1366407603assigned 04/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$93.04M
24GClaims1,714,679
24DCodes billed276
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#2 of 69
Median peer was paid$9.76M
This provider vs. median9.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 222,787 | $4.13M | |
| 2019 | 176,137 | $7.63M | |
| 2020 | 158,154 | $9.42M | |
| 2021 | 265,735 | $15.68M | |
| 2022 | 309,313 | $20.37M | |
| 2023 | 329,052 | $20.67M | |
| 2024incomplete | 253,501 | $15.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 174,219 | 154,065 | $30.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 89,502 | 74,944 | $13.91M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.5% | 60,520 | 50,386 | $4.17M |
| 71045 | Radiologic examination, chest; single view | 4.4% | 29,145 | 24,373 | $4.09M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 20,485 | 18,982 | $3.41M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.2% | 13,998 | 11,234 | $2.96M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.1% | 2,905 | 2,525 | $2.89M |
| 71046 | Radiologic examination, chest; 2 views | 2.2% | 16,506 | 14,643 | $2.08M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.1% | 5,052 | 3,482 | $1.97M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 21,442 | 18,100 | $1.95M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 4,394 | 3,575 | $1.64M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.4% | 9,396 | 7,026 | $1.30M |
264 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 6,712 | $1.15M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 15,780 | $1.09M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.1% | 1,717 | $1.05M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.0% | 5,661 | $954K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,271 | $926K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 485 | $873K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 180,334 | $802K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,745 | $739K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 22,660 | $724K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,537 | $665K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 135,735 | $652K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,247 | $619K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,492 | $604K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 21,587 | $584K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,450 | $546K |
| 36415 | Collection of venous blood by venipuncture | <1% | 199,086 | $453K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,008 | $428K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,487 | $395K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,991 | $391K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,704 | $369K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,605 | $328K |
| 36591 | <1% | 4,605 | $312K | |
| 80076 | <1% | 56,196 | $270K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,588 | $262K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,658 | $248K |
| 84484 | <1% | 29,019 | $245K | |
| 99217 | <1% | 471 | $225K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,055 | $209K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,722 | $203K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,049 | $201K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,442 | $199K |
| 80053 | Comprehensive metabolic panel | <1% | 28,234 | $185K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,639 | $182K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 32,283 | $176K |
| 99219 | <1% | 297 | $173K | |
| 87660 | <1% | 9,496 | $159K | |
| 87480 | <1% | 9,488 | $157K | |
| 87510 | <1% | 9,489 | $156K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 109 | $155K |
| 93308 | <1% | 221 | $153K | |
| 81025 | <1% | 26,125 | $147K | |
| 59025 | Fetal non-stress test | <1% | 562 | $144K |
| 83690 | <1% | 41,578 | $135K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,684 | $131K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 673 | $130K |
| 74018 | <1% | 599 | $129K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,838 | $128K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 58 | $124K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,551 | $123K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12,242 | $121K |
| 99221 | <1% | 194 | $120K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,019 | $115K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 221 | $111K |
| 81001 | <1% | 56,304 | $111K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,096 | $105K |
| 93304 | <1% | 140 | $102K | |
| 80061 | Lipid panel | <1% | 11,915 | $98K |
| 83735 | <1% | 24,858 | $96K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 754 | $94K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 416 | $90K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,251 | $88K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 219 | $87K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,190 | $84K |
| 95886 | <1% | 225 | $54K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,503 | $54K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 375 | $53K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,063 | $52K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 284 | $43K |
| 82728 | <1% | 4,287 | $43K | |
| 64493 | <1% | 94 | $40K | |
| 86481 | <1% | 559 | $38K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 287 | $38K |
| 87081 | <1% | 4,171 | $38K | |
| 93325 | <1% | 2,093 | $38K | |
| 92523 | <1% | 219 | $35K | |
| 80050 | General health panel | <1% | 338 | $35K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 288 | $35K |
| 76820 | <1% | 604 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,960 | $33K |
| 82077 | <1% | 2,891 | $32K | |
| 87653 | <1% | 1,094 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,805 | $31K |
| 80055 | <1% | 795 | $29K | |
| 87536 | <1% | 465 | $27K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 136 | $25K |
| 96416 | <1% | 152 | $25K | |
| 81003 | <1% | 16,834 | $24K | |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 80 | $24K |
| 99224 | <1% | 113 | $23K | |
| 85027 | <1% | 5,302 | $23K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $22K |
| 95951 | <1% | 44 | $22K | |
| 86360 | <1% | 670 | $22K | |
| 77336 | <1% | 141 | $22K | |
| 83550 | <1% | 3,130 | $19K | |
| 86803 | <1% | 1,606 | $19K | |
| 99234 | <1% | 30 | $19K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 366 | $19K |
| 93320 | <1% | 1,431 | $18K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 152 | $18K |
| 62323 | <1% | 31 | $18K | |
| 86359 | <1% | 671 | $17K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 232 | $16K |
| 83540 | <1% | 3,144 | $16K | |
| 86592 | <1% | 3,762 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,573 | $15K |
| 80320 | <1% | 293 | $14K | |
| 80361 | <1% | 2,792 | $14K | |
| 80074 | <1% | 319 | $13K | |
| 86850 | <1% | 3,184 | $13K | |
| 84439 | <1% | 1,779 | $13K | |
| 73630 | <1% | 386 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 957 | $12K |
| 86140 | <1% | 3,193 | $11K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 125 | $11K |
| 87800 | <1% | 280 | $11K | |
| 82607 | <1% | 786 | $10K | |
| 91200 | <1% | 60 | $10K | |
| 87077 | <1% | 1,017 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 277 | $9K |
| 64494 | <1% | 58 | $9K | |
| 83655 | <1% | 654 | $9K | |
| 84460 | <1% | 2,693 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $7K |
| 93660 | <1% | 13 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 78 | $6K |
| 87634 | <1% | 99 | $6K | |
| 96417 | <1% | 67 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 41 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 709 | $5K |
| 96367 | <1% | 136 | $5K | |
| 82043 | <1% | 1,596 | $5K | |
| 82565 | <1% | 3,025 | $5K | |
| 96130 | <1% | 56 | $5K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 56 | $5K |
| 97803 | <1% | 60 | $5K | |
| 82962 | <1% | 1,899 | $4K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 86 | $4K |
| 82950 | <1% | 1,109 | $4K | |
| 84703 | <1% | 718 | $4K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 169 | $4K |
| 95885 | <1% | 14 | $4K | |
| 92567 | <1% | 30 | $4K | |
| 85379 | <1% | 506 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 116 | $4K |
| 84520 | <1% | 2,763 | $3K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,165 | $3K |
| 82378 | <1% | 301 | $3K | |
| 84450 | <1% | 1,154 | $3K | |
| 81514 | <1% | 645 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $3K |
| 80143 | <1% | 219 | $3K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 35 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| 80179 | <1% | 206 | $3K | |
| 80365 | <1% | 441 | $2K | |
| 86706 | <1% | 252 | $2K | |
| 80354 | <1% | 208 | $2K | |
| 87186 | <1% | 369 | $2K | |
| 82784 | <1% | 215 | $2K | |
| 85652 | <1% | 998 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 214 | $2K |
| 73522 | <1% | 47 | $2K | |
| 72110 | <1% | 70 | $2K | |
| 84481 | <1% | 126 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 127 | $2K |
| 80051 | <1% | 1,591 | $2K | |
| 82746 | <1% | 179 | $2K | |
| 64495 | <1% | 43 | $1K | |
| 83615 | <1% | 397 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $1K |
| 95909 | <1% | 16 | $1K | |
| 91010 | <1% | 12 | $1K | |
| 87340 | <1% | 164 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 68 | $1K |
| 84702 | <1% | 135 | $1K | |
| 84100 | <1% | 231 | $1K | |
| 73521 | <1% | 21 | $912.12 | |
| 97597 | <1% | 19 | $904.25 | |
| 72100 | <1% | 21 | $862.42 | |
| 86364 | <1% | 207 | $843.67 | |
| 96402 | <1% | 122 | $822.52 | |
| 80355 | <1% | 66 | $800.21 | |
| 72050 | <1% | 14 | $741.94 | |
| 87205 | <1% | 248 | $661.14 | |
| 82570 | <1% | 163 | $646.51 | |
| 82533 | <1% | 57 | $604.06 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 16 | $571.20 |
| 85610 | <1% | 235 | $568.22 | |
| 87210 | <1% | 188 | $536.49 | |
| 84146 | <1% | 59 | $520.31 | |
| 86258 | <1% | 66 | $506.69 | |
| 86038 | <1% | 53 | $494.38 | |
| 84156 | <1% | 164 | $465.43 | |
| 77072 | <1% | 12 | $460.08 | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 143 | $457.07 |
| 85046 | <1% | 104 | $443.72 | |
| 87070 | <1% | 40 | $442.12 | |
| 82947 | <1% | 153 | $398.40 | |
| 86200 | <1% | 41 | $383.93 | |
| 83020 | <1% | 30 | $359.46 | |
| J3490 | Unclassified drugs | <1% | 156 | $356.85 |
| 82977 | <1% | 53 | $349.89 | |
| 86762 | <1% | 27 | $324.23 | |
| 83521 | <1% | 14 | $317.38 | |
| C1729 | Catheter, drainage | <1% | 20 | $280.80 |
| 86696 | <1% | 13 | $279.66 | |
| 93041 | <1% | 28 | $272.76 | |
| 82785 | <1% | 18 | $271.05 | |
| 86235 | <1% | 40 | $257.71 | |
| 73120 | <1% | 12 | $243.72 | |
| 86900 | <1% | 97 | $229.30 | |
| 86901 | <1% | 97 | $229.30 | |
| 86160 | <1% | 12 | $213.12 | |
| 86376 | <1% | 14 | $209.04 | |
| 86334 | <1% | 13 | $205.70 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 26 | $195.69 |
| 96137 | <1% | 22 | $159.21 | |
| 96136 | <1% | 22 | $159.21 | |
| 86695 | <1% | 13 | $157.88 | |
| 85018 | <1% | 24 | $155.94 | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 178 | $115.00 |
| 83605 | <1% | 17 | $104.13 | |
| 84550 | <1% | 17 | $79.23 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 16,017 | $69.43 |
| 84165 | <1% | 14 | $58.22 | |
| 81015 | <1% | 17 | $45.75 | |
| 86225 | <1% | 21 | $36.08 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,842 | $26.46 |
| 82550 | <1% | 17 | $25.94 | |
| A0425 | Ground mileage, per statute mile | <1% | 274 | $16.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 249 | $14.40 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $14.32 |
| J2704 | Injection, propofol, 10 mg | <1% | 231 | $7.82 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,003 | $6.17 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 233 | $5.29 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 165 | $3.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 478 | $3.52 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 233 | $0.09 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 760 | $0.06 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 13 | $0.02 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,372 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 483 | $0.00 |
| 93321 | 0% | 367 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 104 | $0.00 |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 31 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 336 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 11,013 | $0.00 |
| A9270 | Non-covered item or service | 0% | 414 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 857 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 79 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 157 | $0.00 |
| 96131 | 0% | 21 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 71 | $0.00 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 0% | 99 | $0.00 |
| 84436 | 0% | 58 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 19 | $0.00 |
| 83880 | 0% | 23 | $0.00 | |
| 84480 | 0% | 57 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 16 | $0.00 |
| 84153 | 0% | 12 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRISSER, STANTON (ACFO)
Parent organizationPARKVIEW HOSPITAL, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.